AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2

Sitasto M 50/1000 Tablet PR

Prescription Icon
Prescription Required

Marketer

Acugen Lifesciences Pvt Ltd

Salt Composition

Sitagliptin (50mg) + Metformin (1000mg)

Overview Sitasto M 50/1000 Tablet PR

Diabetac Duo 50/1000 tablets are a dual-action medication managing elevated blood glucose in type 2 diabetes. This dual approach helps mitigate serious diabetic complications like renal impairment and vision loss, potentially lowering heart attack and stroke risks. Diabetac Duo may be used independently or in conjunction with other diabetic treatments. Optimal results require a balanced diet and regular physical activity. Dosage is individualized based on your health status, glucose levels, and other medications. Consuming it with food minimizes digestive discomfort. Consistent daily dosing at the same time maximizes effectiveness; discontinue only under physician guidance. Adherence to your doctor's dietary and exercise plan is crucial for effective diabetes management. Lifestyle choices are key to controlling diabetes. Common side effects include nausea, diarrhea, vomiting, indigestion, headache, and throat irritation. Low blood sugar (hypoglycemia) is a potential side effect, particularly when combined with insulin or sulfonylureas; learn its symptoms and management. This medication isn't suitable for everyone. Inform your doctor about prior kidney, liver, or heart disease, pancreatic issues, or excessive alcohol consumption before starting. Pregnant or lactating individuals should consult their physician. Interactions with other medications are possible; disclose all medications to ensure safety. Alcohol should be limited due to its potential to lower blood sugar. Your doctor will monitor your renal function and blood glucose levels throughout treatment.

Uses of Sitasto M 50/1000 Tablet PR

Managing type 2 diabetes

Major Benefits of Sitasto M 50/1000 Tablet PR:

Always follow your physician's instructions or consult the product labeling for usage guidelines. Administer Sitasto M 50/1000 Tablet PR with a meal.

Common Side effects of Sitasto M 50/1000 Tablet PR:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Sitasto M 50/1000 Tablet PR:

Follow your physician's instructions or consult the product label for usage guidelines. Administer Sitasto M 50/1000 Tablet PR with a meal.

How Sitasto M 50/1000 Tablet PR works:

Sitasto M 50/1000 PR tablets combine sitagliptin and metformin to manage blood sugar. Sitagliptin boosts insulin production by the pancreas, enhances insulin utilization, and decreases hepatic glucose output. Metformin, a biguanide, reduces liver glucose production, slows intestinal glucose absorption, and improves insulin sensitivity. This dual action leads to superior glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Sitasto M 50/1000 Tablet PR with alcohol is not advisable due to safety concerns.

PregnancyPregnancyCONSULT YOUR DOCTOR

The use of Sitasto M 50/1000 Tablet PR during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible risks prior to prescribing. Physician consultation is advised.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

The use of Sitasto M 50/1000 Tablet PR while breastfeeding is likely inadvisable. Available human data indicates potential drug transfer to breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Patients with kidney impairment should use Sitasto M 50/1000 Tablet PR cautiously, potentially requiring dosage modification. Physician consultation is recommended. The medication is contraindicated in individuals with severe kidney disease. Close monitoring of renal function is advised during treatment.

LiverLiverUNSAFE

The use of Sitasto M 50/1000 Tablet PR is likely inadvisable for individuals with hepatic impairment and should be avoided. Medical advice is recommended.

What if you forget to take Sitasto M 50/1000 Tablet PR :

Should you forget to take a Sitasto M 50/1000 Tablet PR, administer it at your earliest convenience. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual medication regimen. Avoid taking a double dose.

Facts to Know About Sitasto M 50/1000 Tablet PR

LabelValue
Addiction potential None.
Treatment Category Medication for diabetes

FAQs on Sitasto M 50/1000 Tablet PR

Sitasto M 50/1000 Tablet PR combines sitagliptin and metformin to manage type 2 diabetes mellitus in adults. This medication helps regulate blood sugar when used alongside a healthy diet and exercise regimen. Metformin reduces liver glucose production and enhances insulin sensitivity. Sitagliptin works by suppressing DPP4, thereby boosting pancreatic insulin secretion. This formulation is unsuitable for individuals under 18.
Prolonged Sitasto M 50/1000 Tablet PR use can indeed lead to vitamin B12 deficiency. This medication impedes the stomach's absorption of vitamin B12. Untreated deficiency may result in anemia and neurological complications, manifesting as tingling or numbness in the extremities, muscle weakness, urinary dysfunction, cognitive changes, and impaired balance. To mitigate these risks, supplemental vitamin B12 is recommended by some experts at least annually.
Sitasto M 50/1000 Tablet PR administration may result in frequent adverse events including hypoglycemia, taste disturbances, nausea, abdominal pain, diarrhea, cephalalgia, and upper respiratory infections. Rare, yet potentially serious, side effects such as lactic acidosis may also occur. Prolonged therapy may additionally cause vitamin B12 deficiency.
Individuals with hypersensitivity to any Sitasto M 50/1000 Tablet PR ingredient or inactive component should not use this medication. Its use is contraindicated in patients experiencing severe renal or hepatic dysfunction, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Sitasto M 50/1000 Tablet PR with alcohol is unsafe and may heighten the risk of lactic acidosis.
Retain this medication within its original, sealed container. Follow the storage guidelines provided on the packaging. Discard any leftover medication. Prevent access by children, pets, and others.
Sitagliptin/metformin combination tablets (e.g., Sitasto M 50/1000) can cause lactic acidosis, a serious medical condition characterized by excessive blood lactic acid. Also termed metformin-associated lactic acidosis (MALA), this is an uncommon adverse event primarily linked to metformin use. Consequently, its use is contraindicated in individuals with impaired kidney function, the elderly, or those who consume significant quantities of alcohol. Symptoms may manifest as muscle aches or weakness, vertigo, fatigue, cold extremities, dyspnea, nausea, emesis, abdominal discomfort, or bradycardia. The appearance of such symptoms necessitates immediate cessation of Sitagliptin/metformin therapy and prompt medical attention.
Sitasto M 50/1000 Tablet PR combines sitagliptin and metformin to manage type 2 diabetes mellitus in adults. This medication enhances blood sugar control when used with a healthy diet and regular physical activity. Metformin reduces liver glucose production and improves insulin responsiveness. Sitagliptin's action involves DPP4 enzyme inhibition, thereby boosting pancreatic insulin secretion. This formulation is unsuitable for individuals under 18.
Sitasto M 50/1000 Tablet PR may cause common adverse reactions including hypoglycemia, altered taste perception, nausea, abdominal pain, diarrhea, headache, and upper respiratory infections. Rare but potentially serious side effects such as lactic acidosis may also occur. Prolonged use is associated with a risk of vitamin B12 deficiency.
Patients with hypersensitivity to Sitasto M 50/1000 Tablet PR constituents or inactive ingredients should not use this medication. Its administration is contraindicated in individuals experiencing severe renal or hepatic dysfunction, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Sitasto M 50/1000 Tablet PR with alcohol is unsafe due to a heightened risk of lactic acidosis.
Indeed, Sitasto M 50/1000 Tablet PR can result in lactic acidosis, a serious medical condition characterized by excessive lactic acid buildup in the bloodstream. Also termed MALA (Metformin-associated lactic acidosis), this is an infrequent adverse reaction to metformin, prompting its avoidance in individuals with pre-existing kidney impairment, the elderly, or those consuming substantial alcohol. Lactic acidosis symptoms might encompass muscle aches or weakness, lightheadedness, fatigue, cold extremities, respiratory distress, queasiness, vomiting, abdominal discomfort, or a slow pulse. Should these symptoms appear, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged Sitasto M 50/1000 Tablet PR use can indeed lead to vitamin B12 deficiency. This medication impedes the stomach's absorption of vitamin B12. Untreated deficiency may result in anemia and neurological complications, manifesting as tingling or numbness in the extremities, muscle weakness, urinary dysfunction, cognitive changes, and impaired balance. Preventive measures, proposed by some studies, include annual supplemental vitamin B12 intake.
Store the medication in its original, tightly sealed container or packaging. Follow the storage instructions provided on the label or packaging. Discard any leftover medication. Prevent access by children, pets, and others.
Sitagliptin and Metformin, combined as Sitasto M 50/1000 Tablet PR, manage type 2 diabetes mellitus in adults. This medication enhances blood sugar control when used with a healthy diet and exercise regimen. Metformin reduces liver glucose production and improves insulin responsiveness. Sitagliptin works by suppressing DPP4, thereby boosting pancreatic insulin secretion. This formulation is unsuitable for individuals under 18.
Taking Sitasto M 50/1000 Tablet PR may cause frequent side effects including low blood sugar, taste changes, queasiness, abdominal discomfort, loose stools, headaches, and upper respiratory illnesses. Rarely, but seriously, lactic acidosis can occur. Prolonged use might also result in Vitamin B12 deficiency.
Patients with hypersensitivity to Sitasto M 50/1000 Tablet PR constituents or inactive ingredients should not use this medication. Furthermore, its administration is contraindicated in individuals with severe renal or hepatic dysfunction, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Sitasto M 50/1000 Tablet PR with alcohol is unsafe and may heighten the risk of lactic acidosis.
Indeed, Sitasto M 50/1000 Tablet PR carries a risk of lactic acidosis, a serious medical condition resulting from excessive blood lactic acid. This complication, also termed metformin-associated lactic acidosis (MALA), is infrequent but necessitates caution. Therefore, its use is contraindicated in individuals with pre-existing kidney impairment, the elderly, or those consuming significant alcohol. Warning signs of lactic acidosis can manifest as muscular discomfort or weakness, vertigo, fatigue, cold extremities, respiratory distress, nausea, emesis, abdominal pain, or bradycardia. Should such symptoms appear, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged Sitasto M 50/1000 Tablet PR administration can indeed lead to vitamin B12 deficiency. This medication impairs the stomach's absorption of vitamin B12. Consequently, untreated deficiency may manifest as anemia and neurological complications, including peripheral paresthesia (tingling and numbness in the extremities), weakness, urinary dysfunction, cognitive changes, and ataxia (impaired balance). To mitigate these risks, supplemental vitamin B12 intake, at least annually, is recommended by some studies.
Store the medication in its original, tightly sealed container, following the storage guidelines provided on the packaging. Discard any remaining medicine. Ensure the medication remains inaccessible to children, pets, and others.
Sitasto M 50/1000 Tablet ...
155
MRP 180
13% off